Latest Biotechnology News

Page 5 of 101
Arovella has moved its off-the-shelf CAR-iNKT therapy ALA-101 into human testing, dosing the first patient in the phase 1 SAPPHIRE trial. The study will now test safety and early signs of activity, with initial data expected in early 2027.
Ada Torres
Ada Torres
27 Oct 2026
Actinogen Medical has received an A$10.84 million R&D tax rebate, leaving it with A$21.9 million in pro forma cash and no debt just weeks before its pivotal Alzheimer’s readout. The company says topline XanaMIA results remain due in mid-November.
Ada Torres
Ada Torres
26 Oct 2026
AdAlta is nearing two important development milestones for its EW-001 CAR-T therapy, with a US FDA pre-IND meeting scheduled for 4 November and Australian manufacturing runs expected before year-end. The progress comes with encouraging but early Chinese clinical data, while cash of A$0.65 million leaves limited room for delay.
Ada Torres
Ada Torres
26 Oct 2026
Invex Therapeutics has agreed to acquire New Zealand biotech Rekover Therapeutics for shares and performance rights, adding a planned Phase 2a multiple sclerosis trial to its neurology portfolio. The transaction is paired with a $10 million placement, but would substantially expand the company’s share count and requires shareholder approval.
Ada Torres
Ada Torres
26 Oct 2026
Immutep’s FY2026 filing puts the full cost of the failed TACTI-004 Phase III trial on display: a larger loss, an impaired efti asset and a manufacturing investigation that remains unresolved. The company has A$68.9 million in cash and term deposits, which it forecasts will fund operations into the first half of calendar 2028 under current plans.
Ada Torres
Ada Torres
26 Oct 2026
New research from the NEPTUNE cohort has strengthened the biological rationale for Dimerix’s DMX-200 kidney drug, linking CCR2 activity and urinary MCP-1 levels with poorer outcomes in FSGS. The findings support the drug’s mechanism, but do not yet demonstrate Phase 3 efficacy.
Ada Torres
Ada Torres
23 Oct 2026
Zoono Group is seeking up to A$1.61 million from a non-renounceable rights issue after completing a separate A$250,000 placement, with its offer document warning of material uncertainty around going concern. The funds are intended to support shelf-life extension projects, intellectual property and working capital, but investors face dilution and an unresolved legal case.
Ada Torres
Ada Torres
23 Oct 2026
Paradigm’s administrators have asked the Supreme Court of Western Australia for up to three more months to assess sale and recapitalisation proposals. Without the extension, they say they would have no alternative but to recommend winding up the biotech.
Ada Torres
Ada Torres
23 Oct 2026
Arovella has released two clinical batches of its off-the-shelf CAR-iNKT therapy, activated two trial sites and begun screening patients ahead of expected first dosing in October. The biotech ended September with A$11.6 million in cash, rising to about A$15.63 million pro forma after an R&D rebate.
Ada Torres
Ada Torres
23 Oct 2026
Starpharma has submitted its European trial application for DEP HER2-Lu and completed manufacture of clinical material, bringing its lead radiopharmaceutical closer to first patient dosing. The biotech also took control of Petalion, collected a Radiopharm option fee and finished the quarter with AUD $34.4 million in cash.
Ada Torres
Ada Torres
22 Oct 2026
Recce Pharmaceuticals has granted Arrotex exclusive rights to commercialise its investigational RECCE 327 topical gel in Australia and New Zealand. The agreement offers a potential profit-share stream, but no upfront payments, sales forecast or approval have been disclosed.
Ada Torres
Ada Torres
22 Oct 2026
Arovella Therapeutics has received a $4.03 million FY2026 R&D tax refund, giving the clinical-stage biotech additional cash as it advances its lead therapy ALA-101 towards first-patient dosing. The payment arrives without any accompanying clinical data or disclosed update to the company’s cash runway.
Ada Torres
Ada Torres
22 Oct 2026

Browse the archive

Full archive